PepGen has released its Q3 Canadian community newsletter that summarizes key Duchenne muscular dystrophy and DM1 updates, including details about their CONNECT clinical trials.
The CONNECT 1 and CONNECT 2 clinical studies are designed to evaluate the potential safety and efficacy of PGN-EDO51 in a broad population of boys and young men with DMD amenable to exon 51 skipping:
- CONNECT1, our Canadian study, will be open for recruitment soon, and details of the study will be shared with the community.
- Plans for CONNECT2, our global study, are ongoing.